Oklahoma Proton Center Celebrates Milestone Achievement: 5,000th Patient Successfully Treated

OKLAHOMA CITY, April 2, 2024 /PRNewswire/ — In a momentous occasion, Oklahoma Proton Center, a leading provider of cutting-edge proton therapy, recently completed treatment on their 5,000th patient.

Oklahoma Proton Center is one of a few proton centers in the country to reach the 5,000 patient milestone. The facility opened in 2009 as the 6th proton center in the country and remains one of just 5 centers in the southwest.

This significant milestone underscores the Proton Center’s unwavering commitment to advancing cancer care and providing state-of-the-art treatment options.

David Raubach, Chief Development Officer at the Center, acknowledged the significance of the day:

“The team at Oklahoma Proton Center is one of the most experienced in the country. The facility has been a pioneer in proton therapy for a decade and continues to lead the way in treating new disease sites and developing advanced treatment protocols. We are excited for where the future leads.”

Proton therapy has emerged as a standard of care approach to for the treatment of many solid cancers, offering enhanced precision and reduced side effects compared to traditional radiation therapies. The Oklahoma Proton Center treats over 600 patients annually from around Oklahoma and across multiple disease sites.

Dr. John Chang, Medical Director at Oklahoma Proton Center remarked, “Reaching the milestone of treating our 5000th patient is a moment of great pride for our team. It reflects the technological advancements in proton therapy and the dedication of our staff to provide the highest quality care to each patient.”

Proton therapy, a highly precise form of radiation therapy, targets tumors with remarkable accuracy, minimizing damage to surrounding healthy tissues and is utilized regularly at most of the top cancer centers across the U.S. This advanced treatment modality has demonstrated efficacy in various cancer types, including prostate, breast, brain, lung as well as many others.

Richard Fransen was the 14th patient treated at Oklahoma Proton Center, finishing treatment in 2009 and now serves as chairman of the board of directors for the foundation that owns the not-for-profit facility. He spoke at the ceremony celebrating the 5,000th patient:

“I was one of the original fifteen – a group of fifteen patients who agreed to be the first patients to get treated at the facility. I remember it was an exciting time, but also there was some nervousness being so early in the process. We knew this facility could be something special for the city and for the field of cancer care though. I’m proud to be here to celebrate so many lives changed since our first little group finished treatment fifteen years ago.”

Oklahoma Proton Center has been at the forefront of proton therapy innovation, and is committed to significant investment in research, education, and patient care going forward as it positions itself as a leader in the field of cancer treatment.

About Oklahoma Proton Center:

Oklahoma Proton Center is a leading provider of proton therapy, dedicated to advancing cancer care through cutting-edge technology, research, and patient-centric care. With a commitment to innovation and excellence, the Proton Center has become a trusted destination for cancer treatment, providing hope and healing to patients and their families.

CONTACT: 

David Raubach
Chief Development Officer
Oklahoma Proton Center
Phone: (918) 798 – 9160

View original content to download multimedia:https://www.prnewswire.com/news-releases/oklahoma-proton-center-celebrates-milestone-achievement-5-000th-patient-successfully-treated-302106381.html

SOURCE Oklahoma Proton Center

Staff

Recent Posts

CannaPharmaRX Provides Corporate Update and Outlines Growth Strategy for 2026

CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an…

11 hours ago

TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

14 hours ago

TruuCONNECT NJ Statewide Digital Hub Empowers Users to Find Verified, Local Community Resources and Support – Anonymously and in Real Time

MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…

14 hours ago

Nuvo Unveils Large-Scale AI-Ready Pregnancy Dataset Built on Real-World Maternal and Fetal Physiology

Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…

14 hours ago

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…

14 hours ago

RxAnte Announces Strategic Growth Investment from Primus Capital

PORTLAND, Maine, Jan. 12, 2026 /PRNewswire/ -- RxAnte, the leading provider of analytics, software, and…

14 hours ago